Seeking Alpha

Investorideas.com's  Instablog

Investorideas.com
Send Message
www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas, news and research for biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on... More
My company:
Investor Ideas
My blog:
Investor Ideas Newswire
  • Exosomes News; Nano-Scale Bubbles Creating Waves In Diagnostics And Therapeutics (AEMD News) 0 comments
    Dec 17, 2013 11:18 AM | about stocks: AEMD, LLY, LIFE

    New York, NY, Point Roberts, WA - December 17, 2013 (Investorideas.com newswire) Investorideas.com, an investor news and research portal issues an exclusive sector snapshot on the rapidly growing exosome market and opportunities with key insight from Enal Razvi, Ph.D, Biotechnology Analyst and Managing Director of SelectBio U.S.

    For investors unfamiliar with exosomes, they are cell-derived vesicles that are present in most biological fluids including blood and urine, as well as other body fluids. Because the fluids are easily accessible, they can be used as markers for disease progression. Exosomes are described as tiny, nano-scale bubbles that are released from cells capable of intercellular communication.

    "Only five years ago the principals of communicating within the body were hormones, immunology or neurology and now we have found another way of communicating and sending genetic signals between cells," Life Technologies Corp (NASDAQ:LIFE).

    So why is something so small creating such a huge buzz? Two key significant areas of growth in the sector are diagnostics and therapeutics for diseases such as cancer.

    According to a report earlier this year from Select Biosciences, "Exosome research is growing exponentially as researchers from several disparate disciplines are exploring the role of exosomes in inter-cellular communication, immunological responses, stem cell behavior, cancer cell communication, etc. Indeed, the potential of exosomes and other classes of microvesicles as a means of molecular cargo transport is being intensively studied. "

    Enal Razvi, Ph.D, Biotechnology Analyst and Managing Director of SelectBio U.S, one of a few experts covering the space, shared insight with Investorideas.com in a recent conversation.

    When we asked Enal to discuss what publicly traded companies are in this new sector for investors, he said there are only a few to watch including Life Technologies Corp (LIFE) (currently being acquired by Thermo Fisher Scientific), Eli Lilly (LLY) (due to their partnership with Exosome Diagnostics) and Aethlon Medical (AEMD).

    He went on to say, "Investors need to be aware of changes exosomes allow, making companion diagnostics a reality. Exosomes can create a paradigm shift for companion diagnostics based on circulating biomarkers.

    "Five years from now, or sooner, exosomes will become a key diagnostic tool for cancers. If we don't know the origin of tumors; biomarkers can narrow down the source.

    Why investors should pay attention to the space is because exosomes can significantly reduce the cost and increase the compliance, primarily for cancer, and make biopsies for personal medicine longitudinal sense. It becomes a very invasive process for a patient to get ongoing biopsies, so this new method of using exosomes for diagnostics is very exciting for patients.

    Currently the research market for exosomes is about $50 million but this does not account for the opportunities in the diagnostics space which will drive market growth and value creation."

    Aethlon Medical (OTCBB: AEMD) is one of the only companies that may be able to participate in both diagnostics and therapeutics in the exosome space. The company recently announced the launch of Exosome Sciences (NYSE:ESI) as a subsidiary that is advancing exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. Aethlon also attracted two of the best-known thought leaders in the exosome industry to play key roles in the new company.

    "We are well positioned to benefit from the exosome revolution," stated Aethlon Medical Chairman and CEO, Jim Joyce. "We are advancing patented first-in-class therapeutic technology to eliminate the presence of tumor-secreted exosomes that trigger the death of immune cells necessary for combating cancer. On the diagnostic front, our Exosome Sciences research team pioneered the field of exosome biology and is actively advancing a pipeline of next generation diagnostic tools".

    In September of this year, Exosome Diagnostics announced that it entered into a collaboration agreement with Eli Lilly & Co. (NYSE:LLY). "Exosome Diagnostics technology may provide a unique opportunity to gain insight into the biology of complex conditions such as cancer and immune disorders", stated Andrew Schade, Senior Medical Director, Diagnostic and Experimental Pathology at Eli Lilly. He further stated that "Exosome technology enables biofluid molecular sampling and the ability to monitor disease progression in real time. As Lilly explores new ways to pursue patient tailoring, we'll continue to work with partners to expand our capabilities."

    Another company in the space, stem cell therapy development company ReNeuron (LON: RENE)

    reported in early December, "We have highlighted a number of key developments in the period, notably the successful and earlier-than-planned development of a second-generation cryopreserved CTX drug product for our stroke and critical limb ischaemia programmes, our planned world-class cell manufacturing facility in South Wales, the granting of Orphan Drug Designation for our retinitis pigmentosa programme and the accelerated development of our CTX cell-based exosomes therapeutic platform".

    Life Technologies Corp (LIFE) has created a mini documentary series entitled 'Exosomes-The Next Small Thing'. "Exosomes are a very powerful way, a new way of how cells communicate long distance… They are powerful mediators that carry all the signaling and machinery necessary to change the behavior of the neighboring cells". http://www.lifetechnologies.com/ca/en/home/life-science/cell-analysis/exosomes/exosomes-documentary-episode-1.html

    PDF for Exosomes Market Snapshot: Enal Razvi, Ph.D.

    http://www.genengnews.com/media/pdf/GEN-Biomarket-Trends-Report-Exosomes%20Market-Landscape-2013.pdf

    Bio for Enal Razvi, Ph.D- Biotechnology Analyst and Managing Director of SelectBio U.S

    Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at enal@selectbio.us

    About Aethlon Medical, Inc. (OTCQB:AEMD)

    Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com

    News source: http://www.hispanicbusiness.com/2013/12/4/reports_from_dalian_medical_university_advance.htm

    About InvestorIdeas.com:

    InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense renewable energy and Latin American stocks.

    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

    Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

    Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com

    Sign up for news alerts:

    http://www.investorideas.com/Resources/Newsletter.asp

    Become an Investorideas.com Member http://www.investorideas.com/membership/

    Themes: biotech Stocks: AEMD, LLY, LIFE
Back To Investorideas.com's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.